uniQure NV (NASDAQ:QURE) traded up 5.2% during trading on Thursday . The company traded as high as $7.57 and last traded at $7.50, with a volume of 142,544 shares changing hands. The stock had previously closed at $7.13.

A number of equities research analysts have recently commented on the stock. Chardan Capital reiterated a “buy” rating on shares of uniQure NV in a research report on Monday, July 18th. Piper Jaffray Cos. reiterated a “buy” rating on shares of uniQure NV in a research report on Thursday, June 30th. Oppenheimer Holdings Inc. reiterated an “outperform” rating and issued a $23.00 target price on shares of uniQure NV in a research report on Wednesday, June 15th. WallachBeth Capital reduced their target price on shares of uniQure NV from $60.00 to $35.00 and set a “buy” rating for the company in a research report on Wednesday, June 15th. Finally, Cowen and Company reiterated a “buy” rating on shares of uniQure NV in a research report on Tuesday, June 14th. One research analyst has rated the stock with a hold rating and ten have given a buy rating to the stock. uniQure NV currently has a consensus rating of “Buy” and a consensus target price of $30.80.

The firm’s 50 day moving average price is $8.75 and its 200 day moving average price is $12.69. The company’s market capitalization is $177.95 million.

uniQure NV (NASDAQ:QURE) last issued its earnings results on Tuesday, May 31st. The company reported ($0.93) EPS for the quarter, missing the consensus estimate of ($0.82) by $0.10. On average, equities analysts anticipate that uniQure NV will post ($3.14) EPS for the current year.

Uniqure NV is a pharmaceutical company based in the Netherlands. It is primarily engaged in the field of gene therapy for orphan diseases. The Company is focused on patients suffering from genetic or acquired diseases by directing the expression of a therapeutic protein or restoring the expression of a missing protein through a single administration.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.